FDA
-
-
-
-
-
-
-
Fractyl Health reports one-year weight maintenance data after GLP-1 stop
-
-
-
-
-
-
-
Fractyl Health gets approval for first gene therapy trial in type 2 diabetes
-
-
-
-
-
-
-
Fractyl Health Enters a Catalyst-Rich 2026 Positioned to Define the Post-GLP-1 Weight Maintenance Therapeutic Category
-
-
-
-
-
-
-
Fractyl Health Announces Groundbreaking Data from REMAIN-1 Midpoint Cohort Showing Revita® Maintained Weight Loss After GLP-1 Discontinuation
-
-
-
-
-
-
-
Fractyl Health reports two-year weight loss data from German study
-
-
-
-
-
-
-
Fractyl Health and Bariendo Sign Letter of Intent to Prepare for Potential Offering of Revita® Across its Bariatric and Metabolic Endoscopy Centers Nationwide
-
-
-
-
-
-
-
Fractyl Health Announces Increased Focus on Groundbreaking Revita® Weight Maintenance and Rejuva® Pancreatic Gene Therapy Programs with Potential to Deliver Key Clinical Milestones Across Multiple S
-
334,274 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All


